Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer The CHAI platform extracted ...

ROCKVILLE, Md.--(BUSINESS WIRE)--BrainScope, a leader in brain diagnostics, today announced the successful completion of the proof-of-concept phase for a novel brain activity-based biomarker for the ...

Panome Bio, a CRO, launched MassID™, a cloud-based computational platform designed to improve how researchers process and interpret untargeted LC/MS metabolomics data. The platform is described in a ...

The world is currently undergoing a significant transformation in biomarker science. Biomarker signatures are no longer academic luxury or exploratory afterthoughts; they have matured into strategic ...

Hello, and welcome to Herantis Pharma's Phase Ib Biomarker Data webinar. I am CEO, Antti Vuolanto, joined today by CSO, Henri Huttunen; and CFO, Tone Kvale. We are really excited to discuss yesterday ...